# : A randomized, placebo-controlled trial of the safety and efficacy of tecovirimat for the treatment of patients with monkeypox virus disease

> **NIH NIH N01** · LEIDOS BIOMEDICAL RESEARCH, INC. · 2021 · $9,824,009

## Abstract

The funding supports a clinical trial to identify effective treatments for monkeypox virus disease.  Monkeypox virus is a re-emerging pathogen that causes monkeypox virus disease, a disease of epidemic potential that causes significant morbidity and can result in death. Human monkeypox cases have been increasing in sub-Saharan Africa since 2000 and sporadic outbreaks outside of Africa have occurred, with cases in the US and the UK in 2021. The similarity between MPXV and the variola virus, coupled with concerns about the potential of the variola virus as a potential bioterrorism agent, have placed monkeypox treatments at the forefront of public health and scientific research agendas in many countries.

## Key facts

- **NIH application ID:** 10506292
- **Project number:** 75N91019D00024-P00001-759102000025-5
- **Recipient organization:** LEIDOS BIOMEDICAL RESEARCH, INC.
- **Principal Investigator:** LORI DODD
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $9,824,009
- **Award type:** —
- **Project period:** 2020-09-28 → 2025-09-27

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10506292

## Citation

> US National Institutes of Health, RePORTER application 10506292, : A randomized, placebo-controlled trial of the safety and efficacy of tecovirimat for the treatment of patients with monkeypox virus disease (75N91019D00024-P00001-759102000025-5). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10506292. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*